To investigate the impact of NAT10 on EGFR-TKI resistance in NSCLC cells, shRNA targeting NAT10 was established in the two most resistant cell lines, H1650 and H1975, to reduce its expression and determine whether decreased NAT10 expression would attenuate EGFR-TKI resistance. Here, EGFR is linked to non-small cell lung carcinoma.